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What's already known about this topic? 
 
 Activation of 5-HT3 receptors expressed in GABAergic neurons of the 
spinal cord increases GABA release 
 Inhibition of spinal 5-HT3R decreases pain hypersensitivity in animal 
models of chronic inflammatory and traumatic neuropathic pain  
 
What does this study add? 
 Spinal 5-HT3 receptors facilitate pain transmission and contributes to 
ERKs-mediated spinal sensitization during diabetic neuropathy 
 5-HT3R-mediated pain facilitation during DNP is dependent on spinal 
GABAergic post-synaptic neurotransmission 
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Abstract 
 
Background: Spinal 5-HT3 receptors (5-HT3R) has been implicated in 
chronic pain development. The extent to which 5-HT3R contributes to spinal 
sensitization and pain during diabetic neuropathy (DN) remain elusive and the 
mechanisms subserving the effects of 5-HT3R activation on spinal pain 
processing are still unclear. This study aimed to evaluate the contribution of 
spinal 5-HT3R to pain facilitation and spinal sensitization during DN. 
Moreover, considering the pain facilitation mediated by spinal GABA in DN 
and the increased release of GABA upon 5-HT3R activation, the role of GABA 
as a mediator of 5-HT3R spinal effect was assessed. 
Methods: Mechanical nociception was evaluated by paw pressure test in 
streptozotocin (STZ)-diabetic and control rats after intrathecal (i.t.) 
administration of 5-HT3R antagonist (Y25130). The spinal activation of 
extracellular signal-regulated kinases (ERKs) pathway and the expression of 
5-HT3R, glial fibrillary acidic protein (GFAP; marker of astroglia activation) 
and ionized calcium binding adaptor molecule 1 (IBA-1; marker of microglia 
activation) were evaluated at the peak maximum effect of Y25130. The 
involvement of GABA in the behavioural pain effect of Y25130, was assessed 
in STZ-diabetic animals receiving i.t administrations of muscimol (GABAAR 
agonist).  
Results: Intrathecal administration of Y25130 reverted mechanical 
hyperalgesia and ERK-mediated spinal sensitization in STZ-diabetic rats, 
while no effects were observed in control animals. The spinal activation of 
GABAAR by i.t administration of muscimol abolished Y25130-driven 
antinociception. The expression of IBA-1, GFAP and 5-HT3R was unaltered 
by treatment.  
Conclusion: These findings point for a GABA-dependent pronociceptive role 
of spinal 5-HT3R in this chronic pain condition. 
 
Key-Words: Diabetic neuropathic pain; 5-HT3R; GABA; Pain facilitation; 
ERK1/2, spinal sensitization 
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1. Introduction 
 
Diabetic neuropathic pain (DNP) is a debilitating complication of 
diabetes characterized by spontaneous pain, mechanical hyperalgesia and 
tactile allodynia (Galer et al., 2000). DNP have been mostly attributed to 
damage of peripheral nerves (Chen and Levine, 2001), however several 
studies have showed that functional impairments in spinal nociceptive 
processing account for pain during diabetes (Pertovaara et al., 2001; Chen 
and Pan, 2002; Morgado and Tavares, 2007; Morgado et al., 2010). 
Functional studies using the streptozotocin (STZ)-diabetic rat showed 
that impaired pain responses are accompanied by spontaneous hyperactivity 
and hyperexcitability of nociceptive spinal circuits (Morgado and Tavares, 
2007; Li et al., 2010).  These changes have been attributed to increased 
peripheral input and recruitment of nociceptive ascending pathways (Burchiel 
et al., 1985; Chen and Pan, 2002), to alterations of spinal nociceptive 
modulatory mechanisms (Morgado et al., 2008) and, more recently, to 
impairments in pain modulation from supraspinal areas  (Paulson et al., 2007; 
Morgado et al., 2011b; Silva et al., 2013). Recent studies showed that the 
behavioral hypersensitivity and spinal neuronal hyperexcitability are 
accompanied by persistent activation of descending pain circuits (Morgado et 
al., 2011b; Silva et al., 2013), namely the descending serotoninergic pathways 
arising from the rostroventromedial medulla (RVM) (Morgado et al., 2011b). 
The RVM is a key brainstem relay station of the descending pain modulatory 
circuits, which modulates spinal pain transmission mainly by the release of 
serotonin. Depending on the receptor subtype activated and the pain 
condition serotonin can inhibit or enhance spinal nociceptive transmission 
(Dogrul et al., 2009). The 5-HT3 receptors (5-HT3R), the only 5-HT ionotropic 
receptor with excitatory functions, are expressed in the spinal dorsal horn 
neurons and in the central terminals of primary afferents (Kia et al., 1995). 
Experimental data on 5-HT3R-mediated modulation of spinal nociceptive 
processing during acute pain seem conflicting, with studies dividing between 
anti- and pronociceptive roles (Alhaider et al., 1991; Guo et al., 2014). A pain 
facilitatory role of spinal 5-HT3R has been demonstrated in animal models of 
chronic inflammatory and traumatic neuropathic pain (Rahman et al., 2009; 
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Kim et al., 2014) . 
The mechanisms contributing to spinal 5-HT3Rs-mediated pain 
modulation remain elusive. Studies developed in healthy animals, 
demonstrated that 5-HT3R activation enhances spinal GABA release, which 
by acting on GABA receptors inhibits nociceptive transmission and accounts 
to the attenuated behavioral responses observed after 5HT3R agonist 
intrathecal administration (Alhaider et al., 1991). However, it should be noted 
that chronic pain, including DNP, is accompanied by a shift in spinal GABA 
role, which was shown to exert excitatory instead of inhibitory effects when 
activating the post-synaptic ionotropic GABAA receptor (GABAAR) (Jolivalt et 
al., 2008; Morgado et al., 2008). We hypothesized that GABA release induced 
by 5-HT3R activation may be eliciting pro-nociceptive effects during DNP, 
contributing to pain facilitation.  
We used the STZ-diabetic rat, a rodent model widely used to study 
DNP (Calcutt, 2004), to: i) evaluate the contribution of spinal 5-HT3R to pain 
facilitation and spinal sensitization during DNP; ii) evaluate the involvement of 
GABA on spinal 5-HT3R-mediated effects on pain modulation in DNP. 
  
2. Material and Methods 
 
2.1.  Animals 
 
Male Wistar rats (Charles River, France), weighting 250-350g at the 
beginning of the experiments were used. The animals were housed 1 per 
cage with corncob bedding, in a room with controlled environmental 
conditions (temperature, 22 ± 2ºC; humidity, 55 ± 5%) under a 12-h light/dark 
cycle (lights on from 8 am to 8 pm). Food (diet ref: A04, SAFE) and water 
were available ad libitum. The experiments were licensed by the Portuguese 
Food and Veterinary General Directorate (licence number 
0420/000/000/2012) and were performed in accordance with the ethical 
guidelines of the European Community Council Directive 2010/63/EU and of 
the International Association for the Study of Pain in conscious animals 
(Zimmermann, 1983). 
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2.2.  Induction of diabetes 
 
Animals were made diabetic by a single intraperitoneal (i.p.) injection of 
STZ (60 mg/kg body weight; Sigma-Aldrich, Spain).  Age-matched controls 
received equal volume of vehicle solution (citrate buffer 0.1M, pH 4.5). Three 
days after STZ-injection, glucose concentration was measured in blood 
samples collected from the tail vein using BREEZE® 2 blood glucose 
monitoring system (Bayer Diabetes Care, USA). Only rats with blood glucose 
concentration higher than 270 mg/dl were considered diabetic and included in 
the STZ group. At the sacrifice, blood samples were collected for the 
quantification of plasma glucose (BREEZE® 2, Bayer Diabetes Care, USA) 
and hemoglobin A1C levels (A1CNow+®, Bayer Diabetes Care, USA).  
 
2.3.  Catheter implantation  
 
Three weeks after diabetes induction, a silicon catheter was implanted 
into the lumbar subarachnoid space for intrathecal (i.t.) administrations. 
Animals were deeply anaesthetised with a mixture of ketamine and 
medetomidine (75 mg/kg of ketamine and 1mg/kg of medetomidine, i.p). 
Anesthesia was maintained during the surgical procedure with controlled 
levels of volatile anesthetic (isoflurane; 0.5-2%) in 60% oxygen/air mixture. A 
laminectomy was performed at T8 –T9 levels and a sterile silicone catheter 
(length: 13cm, inside diameter: 0.31mm, outside diameter: 0.64mm) (60-011-
01; Helix Medical Europe SE & Co.KG, Germany) was introduced into the 
subarachnoid space and advanced 2.5–3 cm caudally, until the tip of the 
catheter was positioned at L4 – L5 spinal levels. The other end of the 
intrathecal catheter was sealed, externalized and fixed to the back of the 
neck. Animals were allowed to recover for a week. At the end of experiments, 
during the dissection procedure, the position of the catheter tip was verified 
and only the animals with the catheter correctly positioned at L4 – L5 levels 
were included in the study. 
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2.4.  Behavioural evaluation of mechanical nociception 
 
Four weeks after diabetes induction, mechanical nociception was 
evaluated by paw-pressure test (Randall-Selitto test, Ugo-Basile, Comerio, 
Italy) in STZ-diabetic and age-matched control rats receiving intrathecal 
infusions of saline (n=5) or the 5-HT3R antagonist (Y-25130 hydrochloride, 
n=5) in a dose of 30 fmol. The selection of 5-HT3R antagonist and respective 
dose was performed in accordance with a previous study using the same 
administration route (Guo et al., 2014). The mechanical force, in grams, that 
induced hindpaw withdrawal was recorded before intrathecal injection, at 30 
min, 2h, 4h, 6h and 24h post injection. A 25 μl Hamilton syringe was attached 
to the silicon catheter and 25 μl of saline or 5-HT3R antagonist was slowly 
injected, followed by a flushing with saline to guarantee that all the solution 
was injected. Intrathecal injections were performed under light anaesthesia 
(1.5-3% isoflurane in 60% oxygen/air mixture).  
In order to evaluate GABA involvement in 5-HT3R mediated pain 
modulation, additional groups of STZ-diabetic animals received intrathecal 
administrations of Y25310 (n=5) or saline (n=5), followed by an intrathecal 
administration of the GABAA receptor agonist muscimol (0.3 ug), 30 min 
before the maximum peak effect of Y25310 (3.5 h after Y25310 or saline 
administration). The mechanical nociception was evaluated 30 min after 
muscimol injection. A 10 μl Hamilton syringe was attached to the silicon 
catheter and 10 μl of muscimol was slowly injected, followed by flushing with 
saline to guarantee that all the solution was completely delivered. The dose of 
intrathecal muscimol used was chosen in accordance with previous studies 
using the same administration route (Hwang and Yaksh, 1997; Jolivalt et al., 
2008). 
 
2.5.  Immunohistochemistry 
 
To evaluate the effects of 5-HT3R on spinal sensitization, additional 
groups of control and STZ-diabetic animals were treated with saline or Y-
25130 hydrochloride, as described in 2.4, and sacrificed at the time-point 
showing the maximum effect of treatment. The animals were deeply 
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anaesthetized with a ketamine/medetomidine mixture (75 mg/kg of ketamine 
and 1mg/kg of medetomidine, i.p) and transcardially perfused with 250 ml of 
calcium free Tyrode’s solution, followed by 1000 ml of 4% paraformaldehyde 
in 0.1 M phosphate buffer pH 7.4 (PFA). The spinal segments L4–L5 were 
removed, post-fixed in 4% PFA for 2–4h and transferred to 30% sucrose in 
0.1 M PBS overnight at 4 °C. Coronal sections, 40 μm thick, were obtained 
using a freezing microtome. One in each 4 sections was immunoreacted 
against the subunit A of 5-HT3 receptor (5-HT3RA) or phosphorylated 
extracellular signal-regulated kinases 1 and 2 (pERK1/2, marker of 
nociceptive activity) (Ji et al., 1999), using the avidin–biotin–peroxidase 
method. The sections were initially treated with 1% hydrogen peroxidase for 
20 min in order to inhibit the activity of endogenous peroxidase followed by an 
incubation period of 2h in a blocking solution of 10% normal horse serum 
(NHS) in 0.3% Triton X 25% in PBS (PBST) with 0.1 M glycine. The sections 
were then incubated two overnights at 4ºC in goat anti-5HT3RA (1:250; ref: 
AP16518PU-N; Acris Antibodies) or mouse anti-pERK1/2 (1:1000; ref: 
ab50011; Abcam) primary antibodies diluted in PBST with 2% NHS. After 
being washed in PBST with 2% NHS, the sections were incubated in 
biotinylated horse anti-goat immunoglobulin for 5-HT3RA (Vector 
Laboratories) and horse anti-mouse immunoglobulin for pERK1/2 (Vector 
Laboratories), all diluted at 1:200 in PBST with 2% NHS, for 1h, at room 
temperature. Sections were then washed in PBST, incubated for 1 h in the 
avidin–biotin complex (Vectastain, Vector Laboratories), and stained with 
diaminobenzidine (10 mg diaminobenzidine in 20 ml of Tris–HCl 0.05 M, pH 
7.6 solution with 5 μl of 30% hydrogen peroxide). Sections were mounted on 
gelatin-coated slides, air-dried, and coverslipped with Eukit medium. 
Photomicrographs of sections were obtained by using an optical light 
microscope coupled with a high-resolutions digital camera (Axioskop 40; 
Zeiss, Hertfordshire, UK). Acquisition conditions (objective amplification, light 
intensity, contrast and hue) were maintained constant in all photomicrographs 
captions. The 5-HT3RA expression levels were quantified bilaterally in lamina 
I-V by imunolabelling densitometric analysis (6-8 sections per animal; n=4 per 
experimental group), using Image J software.  For pERK1/2 quantification the 
numbers of pERK1/2-immunoreactive (pERK1/2-IR) cells were counted 
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bilaterally in laminae I–V (9-10 sections per animal; n=3-5 per experimental 
group). Delamination of the spinal cord was performed according to The Rat 
Brain Atlas (Paxinos and Watson, 2007). All analysis were performed by a 
blinded experimenter. 
 
2.6.  Western Blotting 
 
For western blot experiments, control and STZ-diabetic animals received 
intrathecal infusions of saline or Y-25130 hydrochloride, as described in 2.4, 
and were sacrificed by decapitation under deep anaesthesia (75 mg/kg of 
ketamine and 1mg/kg of medetomidine, i.p) at the peak maximum Y25130 
effects (n=3-5 per experimental group). The spinal L4-L5 segments were 
immediately removed and frozen at -80 °C. The spinal segments were then 
homogenized in a lysis buffer (20 mM MOPS, pH 7.0, 2 mM EGTA, 5 mM 
EDTA, 1% Triton X-100) enriched with proteinase and phosphatase inhibitor 
cocktails (1:100; Sigma-Aldrich). Homogenates were centrifuged at 21100g 
for 20 min at 4 °C and the supernatants were collected. The protein 
concentration was quantified using Bradford Assay (Bradford Reagent; ref: 
#500-0205; Bio-Rad), using serial diluted bovine serum albumin (BSA) 
solutions as standards. Samples were heated at 100ºC for 5 min and 50μg 
protein of each sample was loaded onto 12% SDS-polyacrylamide gel, 
separated by electrophoresis and transferred to nitrocellulose membranes. 
The membranes were blocked in 5% BSA for 1 h and incubated overnight at 
4ºC with mouse anti-pERK1/2 (1:5000; ref: ab50011; Abcam), rabbit anti-
ERK1/2 (1:1000, ref: 04/2010; Cell Signalling Technology), goat anti-5HT3RA 
(1:500; ref: AP16518PU-N; Acris Antibodies), mouse anti-α-Tubulin (1:10000; 
ref: T5168; Sigma-Aldrich), mouse anti-glial fibrillary acidic protein (GFAP) 
(1:1000; ref: G3893; Sigma-Aldrich), rabbit anti-ionized calcium binding 
adaptor molecule 1 (IBA1) (1:1000; ref: 019-19741; Wako) and rabbit anti-β-
Actin (1:1000; ref: sc-130657; Santa Cruz Biotechnology) primary antibodies. 
The membranes were washed and incubated for 1h in horseradish 
peroxidase-conjugated secondary antibodies anti-mouse for pERK1/2, GFAP 
and α-Tubulin (1:10000; ref: NA931VS; Amersham), anti-goat for 5HT3RA 
(1:10000; ref: sc-2020, Santa Cruz Biotechnology) or anti-rabbit for IBA-1 and 
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β-Actin (1:10000; ref: NA934VS; Amersham). The pERK1/2/total ERK1/2 ratio 
was calculated to determine the phosphorylated fraction of ERKs. The signal 
was detected using a sensitive chemiluminescence reagent (Clarity Western 
ECL, ref: #170-5061; Bio-Rad). The GFAP and IBA-1 expression was used as 
astroglia and microglia markers, respectively (Ohsawa et al., 2004; 
Brahmachari et al., 2006). The α-Tubulin and β-actin were used as internal 
standards. Images were captured using a ChemiDoc XRS system (Bio-Rad) 
and the densitometric analysis of the bands was performed using Image Lab 
5.1 software (Bio-Rad).  
  
2.7.  Drugs 
 
Streptozotocin was purchased from Sigma-Aldrich, Spain. 5-HT3R 
antagonist Y-25130 hydrochloride and GABAA receptor agonist muscimol 
were purchased from TOCRIS Bioscience, UK. 
 
2.8. Antibodies specificity 
 
The specificity of each primary antibody was previously demonstrated 
(Kanazawa et al., 2002; Ralph et al., 2006; Wang and Hatton, 2009; Fei et al., 
2011; Kaur and Tikoo, 2013; Uslu et al., 2014). Control experiments were 
performed by omission of primary or secondary antibodies. Additionally, for 
western blot experiments, the specificity of the primary antibodies was 
demonstrated by the detection of bands in the expected molecular weight. 
 
2.9.  Statistical analysis 
 
The statistical analysis of data was performed using GraphPad PRISM 
version 6.0. The results of the behavioral evaluation of the effects of 
intrathecal administration of Y25130 on mechanical nociception were 
compared using two-way analysis of variance (ANOVA) repeated measures, 
followed by Tukey post-hoc test for multiple comparisons. The results of the 
behavioral evaluation of the effects of muscimol and of immunohistochemistry 
and the western blots experiments were compared using one-way ANOVA, 
  
 11 
followed by Tukey post-hoc test for multiple comparisons. Independent 
sample t-test was used to compare metabolic parameters and pretreatment 
behavioral data between STZ and control animals. Statistical significance was 
settled at p < 0.05. Results are expressed as mean ± standard error of the 
mean (s.e.m.). 
 
3. Results 
 
3.1.  Metabolic characterization 
 
Four weeks after the induction of diabetes, STZ-diabetic rats presented 
significantly increased blood glucose concentration (STZ: 512.19 ± 10.15 
mg/dL; control: 121.3 ± 7.36 mg/dL; p < 0.0001) and hemoglobin A1C levels 
(STZ: 12.1 ± 0.25%; control: 4.8 ± 0.06% p < 0.0001), along with decreased 
body weights (STZ: 261.5 ± 6.55 g; control: 402.1 ± 5.98 g; p < 0.0001), when 
compared with age-matched control animals (Table S1), which is in 
accordance with previous reports using the same animal model (Courteix et 
al., 1993; Calcutt, 2004; Morgado and Tavares, 2007) and support the 
installation of diabetes. 
 
 
3.2.  Effect of i.t. administration of 5-HT3R antagonist on mechanical 
nociception 
 
Four weeks after diabetes onset, STZ-diabetic rats developed mechanical 
hyperalgesia (Fig 1) , as demonstrated by the significantly lower pretreatment 
paw withdrawal threshold (PWT) of STZ-diabetic animals when compared 
with control animals (STZ: 59.8 ± 3.77 g; control: 103.0 ± 2.49 g; p < 0.0001). 
Intrathecal delivery of Y25130 significantly increased the PWT in STZ-diabetic 
rats, showing an antinociceptive effect of Y25130 during DNP. The 
antinociceptive effects of Y25130 in STZ-diabetic animals were evident at 
0.5h (STZ+Saline: 59.8 ± 5.05 g; STZ+Y25130: 88.4 ± 2.26 g; p < 0.001) and 
had a maximum peak at 4h (STZ+Saline: 61.0 ± 3.22 g; STZ+Y25130: 109.8 
± 7.39 g; p < 0.0001), returning to pretreatment values 6h post-administration 
(STZ+Y25130 pretreatment: 62.2 ± 3.38 g; STZ+Y25130: 71.4 ± 3.29 g; p > 
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0.05). The administration of Y25130 had no effect in the mechanical response 
thresholds of control rats in any time-point evaluated (control+Y25130 
pretreatment: 101.8 ± 4.80 g; control+Y25130 at 0.5h post-injection: 96.6 ± 
9.22 g, control+Y25130 at 4h post-injection: 102.8 ± 6.62, control+Y25130 at 
6h post-injection: 95.2 ± 4.55 g g; p>0.05) (Fig 1).  
 
3.3. Effect of i.t. administration of 5-HT3R antagonist on spinal ERK1/2 
activation 
 
The STZ-diabetic rats receiving saline infusions presented a significantly 
higher number of pERK1/2- IR cells when compared with control animals 
(STZ+Saline: 657.9 ± 37.42; control+Saline: 306.9 ± 58.63, p < 0.01)   (Fig 2). 
Administration of Y25130 to STZ-diabetic animals significantly reduced spinal 
ERK1/2 activation (Fig 2), as demonstrated by the significantly lower number 
of pERK1/2-IR cells observed in the spinal sections of Y25130-treated STZ-
animals (STZ+Saline: 657.9 ± 37.42; STZ+Y25130: 417.0 ± 41.27, p < 0.05) 
(Fig 2a and c-f). The treatment had no effects in the number of pERK1/2-IR 
cells in the spinal cord of control rats (control+Saline: 306.9 ± 58.63; 
control+Y25130: 293.1 ± 44.67, p > 0.05). Western blotting quantification of 
pERK1/2 and ERK1/2 expression in spinal homogenates from STZ-diabetic 
and control animals treated with saline or Y25130 also showed that 
administration of Y25130 significantly reduced spinal ERK1/2 activation in 
STZ-diabetic rats, as demonstrated by the significantly lower phosphorylated 
fraction of ERK1/2 content in STZ-diabetic rats treated with Y25130 
(STZ+Saline: 4.0 ± 1.00; STZ+Y25130: 1.2 ± 0.49; control+Saline: 1.5 ± 0.05; 
control+Y25130: 1.2 ± 0.34, p <0.05) (Fig 2b). 
 
3.4. Effect of i.t. administration of 5-HT3R antagonist on spinal glia 
activation 
 
 In order to evaluate if spinal 5-HT3R antagonism during DNP interferes 
with glia activity, we evaluate the effect of spinal 5-HT3R inhibition on spinal 
GFAP and IBA-1 expression levels. The expression of GFAP was significantly 
lower in STZ-diabetic rats than in controls animals (STZ+Saline: 0.04 ± 0.012; 
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control+Saline: 0.92 ± 0.085; p <0.01) (Fig S1b and c). The expression levels 
of IBA-1 were significantly higher in STZ-animals when compared with control 
rats (STZ+Saline: 1.9 ± 0.08; control+Saline: 1.1 ± 0.05; p <0.01)   (Fig S1a 
and c). The spinal 5-HT3R inhibition did not affect the expression levels of 
GFAP (STZ+Saline: 0.04 ± 0.012; STZ+Y25130: 0.04 ± 0.006; p > 0.05; 
control+Saline: 0.92 ± 0.085; control+Y25130: 0.96 ± 0.21, p >0.05) and IBA-
1 (STZ+Saline: 1.9 ± 0.08; STZ+Y25130: 1.8 ± 0.12; p >0.05; control+Saline: 
1.1 ± 0.05; control+Y25130: 1.2 ± 0.12; p >0.05), neither in STZ-diabetic nor 
in control rats (Fig S1).  
 
3.5. Expression of 5-HT3RA at the spinal dorsal horn 
 
Since 5-HT3R inhibition had differential effects on nociceptive responses 
of STZ-diabetic and control animals, we hypothesized that the selective 5-
HT3R-mediated pain facilitation during DNP could be explained by a possible 
change in the expression of the receptor induced by diabetes. Densitometric 
immunolabelling analysis of spinal 5-HT3RA expression did not reveal 
significant differences between the STZ-diabetic and control rats 
(STZ+Saline: 46.0 ± 1.90; STZ+Y25130: 39.8 ± 2.92; control+Saline: 40.6 ± 
4.77; control+Y25130: 43.6 ± 2.94; p > 0.05) (Fig S2a and c-f). These findings 
were corroborated by western blotting analysis of the receptor expression 
(STZ+Saline: 0.3 ± 0.08; STZ+Y25130: 0.5 ± 0.14; control+Saline: 0.3 ± 0.02; 
control+Y25130: 0.4 ± 0.12; p > 0.05) (Fig S2b).  
 
3.6.  Effect of i.t. administration of GABAAR agonist on the effect of 
spinal 5-HT3R inhibition 
 
Muscimol administration prevented the antinociceptive effect elicited by 
5-HT3R inhibition in STZ-diabetic rats, as showed by the reduction in PWT to 
levels of pretreatment in muscimol+Y25130-treated STZ-animals 
(STZ+Y25130 pretreatment: 60.6 ± 2.46 g; STZ+Y25130 at 4h post-injection: 
109.8 ± 7.39 g; STZ+Y25130+Muscimol at 4h post-injection: 57.0 ± 6.43 g, 
p<0.001 in STZ+Y25130 at 4h post-injection vs the other groups) (Fig 3). 
Muscimol had no effects in the mechanical response thresholds of STZ-
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diabetic animals receiving saline infusions (STZ+Saline pretreatment: 61.0 ± 
3.22 g; STZ+Saline+Muscimol at 4h post-saline injection: 56.0 ± 7.10 g, 
p>0.05) (Fig 3). 
 
Discussion 
 
By using a pharmacological approach to inhibit the 5-HT3R at the 
spinal cord in a validated model of DNP, the present study is the first to 
demonstrate that spinal 5-HT3R activation is involved in pain facilitation and 
contributes to spinal sensitization through the activation of ERK1/2 pathways 
during DNP. The present study also provides new insights into the 
mechanisms underlying 5-HT3R-spinal nociceptive modulation in chronic pain 
by showing that 5-HT3R pronociception is mediated by spinal GABAergic 
signalling. 
The development of persistent pain appears to be dependent, in part, 
upon increased drive of RVM-arising 5-HT descending pathways, which 
leading to activation of 5-HT3Rs at the spinal level, seems to facilitate pain 
transmission during chronic pain (Suzuki et al., 2002; Dogrul et al., 2009).  
The pain behavior detected in the second-phase of the formalin test, but not 
that observed in the first-phase, has been reported to be significantly reduced 
in mice lacking the subunit A of 5-HT3R and in animals receiving intrathecal 
administrations of 5-HT3R antagonists, suggesting an involvement of 5-HT3R 
in pain chronification (Oyama et al., 1996; Zeitz et al., 2002). However, some 
contradictory evidences exist in what concern the role of spinal 5-HT3R in 
pain modulation, with studies demonstrating that spinal 5-HT3R elicits 
antinociceptive effects in acute pain (Glaum et al., 1990; Alhaider et al., 
1991). These findings point for a possible shift in the role of spinal 5-HT3R in 
chronic pain conditions. Our data show that inhibition of spinal 5-HT3R by 
intrathecal administration of a selective 5-HT3R antagonist reverted the 
mechanical hyperalgesia in STZ-diabetic rats. Previous studies using STZ-
diabetic rats reported an increased activation of serotonergic neurons at the 
RVM along with higher spinal serotonin contents during DNP (Morgado et al., 
2011b), suggesting an increased RVM descending serotoninergic drive during 
this chronic pain condition. This may lead to overactivation of spinal 5-HT3R, 
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which, taking into account the pain facilitatory role here reported, is likely to 
contribute to mechanical hypersensitivity associated to DNP. No differences 
were observed in the spinal expression of 5-HT3RA in STZ-diabetic rats, 
which reinforces the hypothesis that 5-HT3R-mediated pain facilitation during 
DNP is likely to be caused by increased serotonin bioavailability rather than 
due to changes in the expression of the receptor. Studies also showed 
unaltered  5-HT3R expression in other chronic pain conditions (Rahman et al., 
2009). Our findings along with the lack of antinociceptive effect of a 5-HT3R 
antagonist in an animal model of traumatic neuropathy, where increased 
descending serotoninergic drive was not verified (Peters et al., 2010), clearly 
point to the important role of enhanced activity of descending serotoninergic 
pathways in spinal 5-HT3R pain facilitation during DNP.  
Increasing evidences show that extracellular signal-regulated kinases 1 
and 2 (ERK1/2) expressed in the spinal cord are involved in nociceptive 
processing and spinal sensitization (Gao and Ji, 2009; Han et al., 2011). In 
fact, ERK1/2 are strongly activated in the spinal dorsal horn following 
peripheral inflammation and tissue/nerve injury and the pharmacological 
blockade of this activation reduces the hypersensitivity otherwise observed in 
these experimental models (Ji et al., 1999; 2002). This activation of ERKs has 
been attributed to the hyperexcitatibility of spinal dorsal horn neurons evoked 
by increased peripheral barrage. This assertion, while reasonable, discards 
the possible contribution of other dorsal horn inputs that are believed to 
regulate dorsal horn excitability, namely the inputs arising from descending 
modulatory pathways. Increased activation of ERK1/2 in STZ-diabetic rats 
was observed in the present study, in agreement with data from a previous 
study (Daulhac et al., 2006). In addition, our findings demonstrate that the i.t. 
administration of 5-HT3R antagonist reverted the increased spinal ERK1/2 
activation in STZ-diabetic rats, pointing for a role of 5-HT3R-mediated 
descending serotoninergic facilitation in spinal sensitization during DNP. 
Consistent with our data, previous studies demonstrated that the depletion of 
spinal 5-HT reduced the formalin evoked flinching and activation of spinal 
ERK1/2 pathways (Svensson et al., 2006). Moreover, intrathecal 
administration of ondansetron (a 5-HT3 receptor antagonist) at doses that 
inhibited formalin-induced flinching also attenuated spinal ERK activation 
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(Svensson et al., 2006). Taken together these findings revealed that spinal 
ERKs activation requires the input from an excitatory serotoninergic pathway 
and is dependent on 5HT3R activity.  
At the spinal cord, 5-HT3R expression seems to be restricted to some 
neuronal subpopulations and primary afferents terminals (Kia et al., 1995), 
with no reported expression in glial cells (Guo et al., 2014). The mechanisms 
underlying 5-HT3R-mediated spinal pain modulation remain elusive. Recently, 
a 5-HT3R-dependent neuronal-glial crosstalk was proposed as a possible 
mechanism underlying pain facilitation induced by the pharmacological 
activation of spinal 5-HT3R in healthy animals (Guo et al., 2014), with an i.t. 
injection of 5-HT3R agonist leading to increased activation of microglia and 
astroglia and the reversion of these effect by treatment with a 5-HT3R specific 
antagonist. In the present study no differences were detected in the activation 
of spinal microglia or astroglia upon i.t. administration of 5-HT3R antagonist in 
STZ-diabetic rats. Our results do not seem to support a role for glia in the 
pronociceptive effects of spinal 5-HT3R, at least in this chronic pain condition. 
Indeed, it is important to note that Guo et al. (2014) studied the role of glial 
cells in the effects of spinal 5-HT3R activation in an acute pain condition and 
no reports exist on the effects of chronic pain in this mechanism. In the 
present study we used an animal model of chronic pain that already presents 
altered spinal glial responses before i.t. administration of 5-HT3R antagonist 
(Daulhac et al., 2006; Tsuda et al., 2008; Wodarski et al., 2009; Morgado et 
al., 2011a). The absence of a normal functioning of glia signalling cascade 
during DNP can contribute to the lack of effects of 5-HT3R on glia activation 
here reported.  
The interplay between 5-HT and GABA was shown to be crucial in 
spinal modulation of nociceptive transmission. The electrical stimulation of 
RVM neurons elicits GABA-mediated inhibitory post-synaptic potentials 
(IPSPs) in primate spinothalamic tract neurons (Giesler et al., 1981). 
Furthermore, the GABAA-R agonist, muscimol, and 2-methyl 5-HT, a non-
selective 5-HTR agonist, was shown to have similar effects on nociceptive 
spinal projection neurons firing elicited by excitatory amino acids (Lei and 
Wilcox, 1990). More recently, 5-HT3R expression was reported in an intrinsic 
GABAergic neuronal subpopulation of the spinal cord, and its activation on 
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these neurons was shown to enhance GABA release (Fukushima et al., 
2009). This enhancement is likely to activate postsynaptic GABAAR, which 
was shown to culminate in antinociception by inhibiting spinothalamic tract 
ascending neurons (Alhaider et al., 1991; Kawamata et al., 2003). If in normal 
conditions GABA seems to play a major inhibitory tone on spinal nociceptive 
transmission, several studies have been showing that persistent pain 
conditions, including DNP, are accompanied by a shift in the role of GABA 
from inhibitory to excitatory, due to the decrease of spinal potassium chloride 
co-transporter 2 (KCC2) expression (Jolivalt et al., 2008; Morgado et al., 
2008). The KCC2 downregulation promotes an accumulation of intracellular 
chloride which causes an outflow of chloride ions upon the binding of GABA to 
GABAAR, leading to neuronal excitation instead of inhibition and contributing 
to the spinal nociceptive hyperactivity observed in DNP (Morgado et al., 
2011a). Our results show that the antinociceptive effects of i.t. administered 5-
HT3R antagonist is abolished by i.t. delivery of muscimol, suggesting that the 
effects elicited by 5-HT3R antagonism are mediated by the reduction of 
GABAAR activation, probably due to a decrease in spinal GABA release.  
In conclusion, the data gathered by the present study suggest that 5-
HT3R-mediated increase in spinal GABAergic transmission, probably due to 
the overactivation of descending serotoninergic pathways, can mediate pain 
facilitation during DNP. This study provides new insights on the mechanisms 
underlying the contribution of spinal 5-HT3Rs to pain modulation during 
chronic pain. Accordingly, and attending to the already reported good 
tolerability and pharmacokinetic profile of 5-HT3Rs inhibitory drugs in the 
clinical practice (McCleane et al., 2003), the use of 5-HT3R antagonists may 
then be considered as a promising pharmacological approach in alleviating 
the mechanical hyperalgesia associated to diabetic neuropathy. 
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Legends 
 
Figure 1 - Effects of intrathecal administration of 5-HT3R antagonist on 
mechanical nociception. *Control (saline and Y25130) vs STZ-diabetic (Saline 
and Y25130); # STZ+ Saline vs all other groups; two symbols p<0.01, three 
symbols p<0.001, four symbols p<0.0001, by Two-Way ANOVA repeated 
measures followed by Tukey post-hoc test for multiple comparisons. 
Figure 2 – Effects of intrathecal administration of 5-HT3R antagonist on 
spinal ERK1/2 activation. (a) Number of pERK1/2-labeled cells in lamina I-V in 
sections from L4-L5 spinal segments; (b) quantification by western blotting of 
pERK1/2 expression in the L4 – L5 spinal cord homogenates and 
representative blots; (c-f) representative photomicrographs of sections from 
spinal segments L4-L5 immunoreacted against pERK1/2 in Control+Saline 
(c), Control+Y25130 (d), STZ+Saline (e) and STZ+Y25130 (f). (e’) 
Representative photomicrograph of high magnification of pERK1/2-labeled 
cells in lamina I-II of L4 spinal segment from STZ+saline rats. Scale bar in f = 
500μm, scale bar in e’= 200μm. #STZ+saline vs control groups; *STZ+saline 
vs STZ+Y25130; one symbol p<0.05, two symbols p<0.01, by One-Way 
ANOVA followed by Tukey post-hoc test for multiple comparisons. 
Figure 3 – Effects of intrathecal muscimol in the antinociception elicited by 
the inhibition of spinal 5-HT3R on STZ-diabetic rat. * STZ+Y25130 vs all other 
groups; three symbols p<0.001 by One-Way ANOVA followed by Tukey post-
hoc test for multiple comparisons. 
Table S1 - Blood glucose concentration, percentage of hemoglobin A1C and 
body weights of STZ-diabetic and control animals. 
Figure S1 – Effects on intrathecal administration of 5-HT3R antagonist on the 
spinal expression levels of GFAP and IBA-1. (a) Quantification by western 
blotting of GFAP expression in the L4 – L5 spinal cord homogenates and 
representative blots; (b) quantification by western blotting of IBA-1 expression 
in the L4 – L5 spinal cord homogenates and representative blots. * Control vs 
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STZ groups; two symbols p<0.01, by One-Way ANOVA followed by Tukey 
post-hoc test for multiple comparisons. 
Figure S2 – Analysis of 5-HT3R subunit A (5-HT3RA) expression. (a) 
Immunolabelling optical density in lamina I-V for 5-HT3RA; (b) quantification 
by western blotting of 5-HT3RA expression in the L4 – L5 spinal cord 
homogenates and representative blots; (c-f) representative photomicrographs 
of sections from spinal segments L4-L5 immunoreacted against 5-HT3RA in 
Control+Saline (c), Control+Y25130 (d), STZ+Saline (e) and STZ+Y25130 (f). 
Scale bar: 500μm. 
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Table S1 - Blood glucose concentration, percentage of hemoglobin A1C and body 
weights of STZ-diabetic and control animals. 
 
Parameters STZ Control 
Blood Glucose concentration (mg/dl) 512.9 ± 10.15ª 121.3 ± 7.36 
Hemoglobin A1C (%) 12.1 ± 0.25ª 4.8 ± 0.06 
Body weight (g) 261.5 ± 6.55ª 402.1 ± 5.98 
Independent sample t test. ªp < 0.0001. 
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Abstract 
 
The abstract should not exceed 250 words and should describe the background, the 
aims, the methods, the results and the conclusions reached. It should contain only 
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standard abbreviations and no references. For Original Manuscripts the following 
subheadings are required: 
      • Background 
      • Methods 
      • Results 
      • Conclusions 
For Reviews the following subheadings are required: 
      • Background and Objective 
      • Databases and Data Treatment 
      • Results 
      • Conclusions 
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Author Contributions 
 
Authors are required to include a statement of responsibility at the end of their 
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